ReCode Therapeutics is a clinical-stage genetic medicines company specializing in the precision delivery of mRNA and gene correction therapeutics. Utilizing its proprietary Selective Organ Targeting (SORT) lipid nanoparticle platform, ReCode aims to enhance the efficacy and potency of genetic medicines by targeting specific organs, tissues, and cells implicated in diseases. The company's lead programs focus on developing inhaled mRNA-based therapies for cystic fibrosis and primary ciliary dyskinesia, addressing genetic mutations that are unresponsive to existing treatments.
Estimated Valuation
Leadership & Board
Currently, no data available
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$29M
Total Amount Raised$29M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$29M
Latest Funding Amount$29M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Funding Round
Sep 29, 2025
Investment
$29.00M
―
Investors
Investment
Similar Companies
A snapshot of private companies similar to ReCode Therapeutics, helping you discover and navigate related company profiles.
